Holdings of iShares Biotechnology ETF
iShares Trust · Original filing · Compare with another fund · Report an error
- Net assets
- 8.1B $ including 8.1B $ in equities, 99.9 %
- Positions
- 246 in 19 countries
- Top ten
- 47.4 % of net assets
- Filed on
- Mar 31, 2026
Portfolio shape
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 101 | Alumis Inc | 530,358 | 11.7M $ | 0.14 % |
| 102 | ZAI LAB LTD | 613,747 | 11.5M $ | 0.14 % |
| 103 | Nurix Therapeutics Inc | 720,848 | 11.2M $ | 0.14 % |
| 104 | Stoke Therapeutics Inc | 331,288 | 10.8M $ | 0.13 % |
| 105 | Intellia Therapeutics Inc | 835,337 | 10.7M $ | 0.13 % |
| 106 | AnaptysBio Inc | 192,136 | 10.7M $ | 0.13 % |
| 107 | Recursion Pharmaceuticals Inc | 3,419,857 | 10.5M $ | 0.13 % |
| 108 | Tyra Biosciences Inc | 272,474 | 10.4M $ | 0.13 % |
| 109 | Relay Therapeutics Inc | 980,266 | 9.8M $ | 0.12 % |
| 110 | Amylyx Pharmaceuticals Inc | 687,536 | 9.6M $ | 0.12 % |
| 111 | Novavax Inc | 1,157,114 | 9.4M $ | 0.12 % |
| 112 | Iovance Biotherapeutics Inc | 2,619,021 | 9.2M $ | 0.11 % |
| 113 | WaVe Life Sciences Ltd | 1,176,186 | 8.5M $ | 0.11 % |
| 114 | Immunocore Holdings PLC | 277,185 | 8.4M $ | 0.10 % |
| 115 | Novocure Ltd | 763,201 | 8.3M $ | 0.10 % |
| 116 | Galapagos NV | 271,893 | 8.2M $ | 0.10 % |
| 117 | Grifols SA | 976,161 | 7.8M $ | 0.10 % |
| 118 | Biohaven Ltd | 917,535 | 7.8M $ | 0.10 % |
| 119 | Nuvation Bio Inc | 1,795,888 | 7.7M $ | 0.09 % |
| 120 | AtaiBeckley Inc | 2,160,067 | 7.6M $ | 0.09 % |
| 121 | Taysha Gene Therapies Inc | 1,672,180 | 7.5M $ | 0.09 % |
| 122 | Sionna Therapeutics Inc | 185,101 | 7.4M $ | 0.09 % |
| 123 | Trevi Therapeutics Inc | 608,481 | 7.3M $ | 0.09 % |
| 124 | Mesoblast Ltd. | 460,143 | 7.1M $ | 0.09 % |
| 125 | Corvus Pharmaceuticals Inc | 473,326 | 6.9M $ | 0.09 % |
| 126 | Olema Pharmaceuticals Inc | 457,751 | 6.8M $ | 0.08 % |
| 127 | Rapport Therapeutics Inc | 217,759 | 6.8M $ | 0.08 % |
| 128 | uniQure NV | 413,699 | 6.8M $ | 0.08 % |
| 129 | Geron Corp | 4,513,103 | 6.7M $ | 0.08 % |
| 130 | Fortrea Holdings Inc | 693,057 | 6.5M $ | 0.08 % |
| 131 | Vir Biotechnology Inc | 704,449 | 6.3M $ | 0.08 % |
| 132 | Xencor Inc | 513,267 | 6.2M $ | 0.08 % |
| 133 | AbCellera Biologics Inc | 1,732,022 | 6M $ | 0.07 % |
| 134 | MBX Biosciences Inc | 199,599 | 6M $ | 0.07 % |
| 135 | Maze Therapeutics Inc | 197,936 | 5.9M $ | 0.07 % |
| 136 | CareDx Inc | 337,886 | 5.9M $ | 0.07 % |
| 137 | Theravance Biopharma Inc | 353,652 | 5.7M $ | 0.07 % |
| 138 | Monte Rosa Therapeutics Inc | 346,430 | 5.7M $ | 0.07 % |
| 139 | KalVista Pharmaceuticals Inc | 276,916 | 5.6M $ | 0.07 % |
| 140 | Janux Therapeutics Inc | 392,349 | 5.5M $ | 0.07 % |
| 141 | Pharvaris NV | 191,961 | 5.4M $ | 0.07 % |
| 142 | MannKind Corp | 2,199,381 | 5.4M $ | 0.07 % |
| 143 | ORIC Pharmaceuticals Inc | 424,422 | 5.4M $ | 0.07 % |
| 144 | Castle Biosciences Inc | 215,689 | 5.3M $ | 0.07 % |
| 145 | Annexon Inc | 952,884 | 5.3M $ | 0.07 % |
| 146 | UroGen Pharma Ltd | 286,041 | 5.1M $ | 0.06 % |
| 147 | Kura Oncology Inc | 628,449 | 5.1M $ | 0.06 % |
| 148 | Inhibrx Biosciences Inc | 75,835 | 5.1M $ | 0.06 % |
| 149 | Stevanato Group SpA | 370,391 | 5.1M $ | 0.06 % |
| 150 | Arbutus Biopharma Corp | 1,119,437 | 5M $ | 0.06 % |
| 151 | Septerna Inc | 200,845 | 4.8M $ | 0.06 % |
| 152 | Alto Neuroscience Inc | 212,677 | 4.8M $ | 0.06 % |
| 153 | Bicara Therapeutics Inc | 236,865 | 4.7M $ | 0.06 % |
| 154 | GH RESEARCH PLC | 334,162 | 4.7M $ | 0.06 % |
| 155 | ArriVent Biopharma Inc | 201,242 | 4.6M $ | 0.06 % |
| 156 | CytomX Therapeutics Inc | 987,397 | 4.6M $ | 0.06 % |
| 157 | Cullinan Therapeutics Inc | 323,429 | 4.6M $ | 0.06 % |
| 158 | Replimune Group Inc | 570,930 | 4.4M $ | 0.05 % |
| 159 | Precigen Inc | 1,104,713 | 4.3M $ | 0.05 % |
| 160 | Arvinas Inc | 403,100 | 4.3M $ | 0.05 % |
| 161 | Savara Inc | 775,563 | 4.2M $ | 0.05 % |
| 162 | Ironwood Pharmaceuticals Inc | 1,173,471 | 4.1M $ | 0.05 % |
| 163 | Phathom Pharmaceuticals Inc | 356,945 | 4M $ | 0.05 % |
| 164 | Zevra Therapeutics Inc | 413,742 | 3.9M $ | 0.05 % |
| 165 | Cytek Biosciences Inc | 868,726 | 3.8M $ | 0.05 % |
| 166 | MeiraGTx Holdings plc | 430,643 | 3.7M $ | 0.05 % |
| 167 | ARS Pharmaceuticals Inc | 463,404 | 3.7M $ | 0.05 % |
| 168 | BioAge Labs Inc | 211,362 | 3.7M $ | 0.05 % |
| 169 | Sana Biotechnology Inc | 1,235,916 | 3.6M $ | 0.04 % |
| 170 | Rigel Pharmaceuticals Inc | 131,031 | 3.5M $ | 0.04 % |
| 171 | ZENAS BIOPHARMA INC | 175,941 | 3.4M $ | 0.04 % |
| 172 | Compass Pathways plc | 612,150 | 3.4M $ | 0.04 % |
| 173 | Fulcrum Therapeutics Inc | 429,371 | 3.3M $ | 0.04 % |
| 174 | OPKO Health, Inc. | 2,882,600 | 3.3M $ | 0.04 % |
| 175 | Solid Biosciences Inc | 446,552 | 3.2M $ | 0.04 % |
| 176 | 4D Molecular Therapeutics Inc | 338,744 | 3.2M $ | 0.04 % |
| 177 | Prothena Corp PLC | 323,349 | 3.1M $ | 0.04 % |
| 178 | Emergent BioSolutions Inc | 376,503 | 3.1M $ | 0.04 % |
| 179 | Myriad Genetics Inc | 662,895 | 3M $ | 0.04 % |
| 180 | Absci Corp | 975,088 | 2.9M $ | 0.04 % |
| 181 | BridgeBio Oncology Therapeutics Inc | 324,513 | 2.9M $ | 0.04 % |
| 182 | Perspective Therapeutics Inc | 693,460 | 2.9M $ | 0.04 % |
| 183 | Aclaris Therapeutics Inc | 766,012 | 2.9M $ | 0.04 % |
| 184 | Altimmune Inc | 926,610 | 2.9M $ | 0.04 % |
| 185 | Vanda Pharmaceuticals Inc | 405,038 | 2.8M $ | 0.03 % |
| 186 | Allogene Therapeutics Inc | 1,145,572 | 2.8M $ | 0.03 % |
| 187 | REGENXBIO Inc | 331,423 | 2.8M $ | 0.03 % |
| 188 | Rocket Pharmaceuticals Inc | 752,567 | 2.7M $ | 0.03 % |
| 189 | Pacific Biosciences of California Inc | 2,021,533 | 2.7M $ | 0.03 % |
| 190 | Lexeo Therapeutics Inc | 457,447 | 2.6M $ | 0.03 % |
| 191 | Alvotech SA | 763,481 | 2.6M $ | 0.03 % |
| 192 | Contineum Therapeutics Inc | 200,362 | 2.6M $ | 0.03 % |
| 193 | Enanta Pharmaceuticals Inc | 205,184 | 2.6M $ | 0.03 % |
| 194 | Lineage Cell Therapeutics Inc | 1,621,430 | 2.6M $ | 0.03 % |
| 195 | Standard BioTools Inc | 2,747,556 | 2.5M $ | 0.03 % |
| 196 | ADC Therapeutics SA | 673,142 | 2.5M $ | 0.03 % |
| 197 | Design Therapeutics Inc | 235,859 | 2.5M $ | 0.03 % |
| 198 | Personalis Inc | 393,153 | 2.5M $ | 0.03 % |
| 199 | Atea Pharmaceuticals Inc | 460,056 | 2.5M $ | 0.03 % |
| 200 | Prime Medicine Inc | 704,092 | 2.5M $ | 0.03 % |
Sector breakdown
- Health care 53.6 %
- Unattributed 46.4 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- United States 88.9 %
- Netherlands 3.4 %
- Denmark 2.1 %
- Bermuda 1.2 %
- Canada 0.8 %
- Germany 0.7 %
- Ireland 0.6 %
- France 0.5 %
- Switzerland 0.4 %
- Cayman Islands 0.4 %
- Singapore 0.1 %
- Jersey 0.1 %
- Other countries 0.6 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | United States | 208 | 7.2B $ | 88.91 % |
| 2 | Netherlands | 4 | 279.1M $ | 3.44 % |
| 3 | Denmark | 2 | 173.1M $ | 2.13 % |
| 4 | Bermuda | 1 | 100.9M $ | 1.24 % |
| 5 | Canada | 4 | 67.1M $ | 0.83 % |
| 6 | Germany | 1 | 53.3M $ | 0.66 % |
| 7 | Ireland | 3 | 50.9M $ | 0.63 % |
| 8 | France | 2 | 42M $ | 0.52 % |
| 9 | Switzerland | 3 | 35.3M $ | 0.44 % |
| 10 | Cayman Islands | 5 | 34.8M $ | 0.43 % |
| 11 | Singapore | 1 | 8.5M $ | 0.11 % |
| 12 | Jersey | 1 | 8.3M $ | 0.10 % |
Cite this page
Titelia. "Holdings of iShares Biotechnology ETF". https://titelia.com/en/funds/S000004350